Robin Guo

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Robin Guo, Lynne D. Berry, Dara L. Aisner et al. · Journal of Thoracic Oncology · 2019 · 172 citations · Full text

Oncology, Met Amplification, Medicine +9

Immunophenotype and Response to Immunotherapy of <i>RET</i>-Rearranged Lung Cancers

Michael Offin, Robin Guo, Stephanie L. Wu et al. · JCO Precision Oncology · 2019 · 116 citations · Full text

Lung Cancers, Ret Rearrangements, Tmb Status +15

Characterization of on-target adverse events caused by TRK inhibitor therapy

D. Liu, James Flory, Andrew Lin et al. · Annals of Oncology · 2020 · 82 citations · Full text

Trk Inhibitor Therapy, Pharmacology, Therapeutic Efficacy +6

<i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance

Robin Guo, Michael Offin, A. Rose Brannon et al. · Clinical Cancer Research · 2020 · 78 citations · Full text

ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage

Lufen Chang, Bingsen Zhou, Shuya Hu et al. · Proceedings of the National Academy of Sciences · 2008 · 61 citations · Full text

Reductive Stress, Genome Instability, Transcriptional Regulation +15